Amendments to the Claims

1. (Currently Amended) A fast-dissolving pharmaceutical composition in a solid dosage form excepting a nanoparticle suspension, comprising micronized (R)- 2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (hereinafter referred to as "AS-3201") having a mean particle size in a range of above 1 μ m to less than about 20 μ m in a ratio of about 0.5% by weight to about 25% by weight of the total weight of the pharmaceutical composition,

wherein when a dissolution percentage of AS-3201 from the composition is measured according to the Paddle method, 50% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

2. (Cancelled)

- 3. (Original) The fast-dissolving pharmaceutical composition according to claim 1, wherein the mean particle size of the micronized AS-3201 is less than about 5 μm .
- 4. (Currently Amended) The fast-dissolving pharmaceutical composition according to claim 1, wherein the mean particle size of the micronized AS-3201 is in the range of above 1 μm about 3 μm about 1.2 μm to about 3 μm.
- 5. (Currently Amended) A fast-dissolving pharmaceutical composition in a solid dosage form excepting a nanoparticle suspension, which comprises micronized AS-3201 having a mean particle size in a range of above 1 μm to less than about 20 10 μm in a ratio of about 0.5% by weight [[-]] to 5% by weight, a diluent in a ratio of about 51% by weight [[-]] to about 93.8% by weight, a disintegrator in a ratio of about 5% by weight [[-]] to about 35% by weight, a binder in a ratio of about 0.5% by weight [[-]] to about 5% by weight, and a lubricant in a ratio of about 0.2% by weight [[-]] to about 4% by weight, relative to the total weight of the pharmaceutical composition,

wherein when a dissolution percentage of AS-3201 from the composition is measured according to the Paddle method, 50% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

6. (Cancelled)

Ø,

- 7. (Original) The fast-dissolving pharmaceutical composition according to claim 5, wherein the mean particle size of the micronized AS-3201 is less than about 5 μ m.
- 8. (Currently Amended) The fast-dissolving pharmaceutical composition according to claim 5, wherein the mean particle size of the micronized AS-3201 is in the range of above 1 μ m about 3 μ m about 1.2 μ m to about 3 μ m.

9-12. (Cancelled)

13. (Currently Amended) A fast-dissolving pharmaceutical composition in a solid dosage form excepting a nanoparticle suspension, which comprises micronized AS-3201 having a mean particle size in a range of above 1 μm to less than about 20 10 μm in a ratio of more than 5% by weight and less than about 25% by weight, a diluent in a ratio of about 16% by weight [[-]] to about 84.3% by weight, a disintegrator in a ratio of about 10% by weight [[-]] to about 50% by weight, a binder in a ratio of about 0.5% by weight [[-]] to about 5% by weight, and a lubricant in a ratio of about 0.2% by weight [[-]] to about 4% by weight, relative to the total weight of the pharmaceutical composition, wherein when a dissolution percentage of AS-3201 from the composition is measured according to the Paddle method, 50% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

14. (Cancelled)

- 15. (Original) The fast-dissolving pharmaceutical composition according to claim 13, wherein the mean particle size of the micronized AS-3201 is less than about $5 \mu m$.
- 16. (Currently Amended) The fast-dissolving pharmaceutical composition according to claim 13, wherein the mean particle size of the micronized AS-3201 is in the range of above 1μm about 3 μm about 1.2 μm to about 3 μm.

17-82. (Cancelled)

89. (Currently Amended) A fast-dissolving pharmaceutical composition in a solid dosage form excepting a nanoparticle suspension, comprising micronized AS-3201 (R)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (hereinafter referred to as "AS-3201") having a mean particle size of in a range of above 1 μm to less than about 20 10 μm in a ratio of about 0.5% by weight to about 25% by weight of the total weight of the pharmaceutical composition, and as a stabilizer at least one acidic substance having an acidity more potent than that of AS-3201, a pKa less than about 5.6,

wherein when a dissolution percentage of AS-3201 from the composition is measured according to the Paddle method, 50% or more of the AS-3201 in the composition is dissolved with 15 minutes from the start of the method.

90. (Currently Amended) The fast-dissolving pharmaceutical composition according to claim 89, wherein the acidic substance is a member selected from the group consisting of citric acid, tartaric acid, maleic acid and phosphoric acetate tartaric acid.

91. (Cancelled)

92. (New) The fast-dissolving pharmaceutical composition according to claim 1, wherein the mean particle size of the micronized AS-3201 is above about 1.2 μ m.

- 93. (New) The fast-dissolving pharmaceutical composition according to claim 1, wherein the mean particle size of the micronized AS-3201 is above about 1.5 μ m.
- 94. (New) The fast-dissolving pharmaceutical composition according to claim 1, wherein the mean particle size of the micronized AS-3201 is in the range of about 1.2 μ m to about 5 μ m.
- 95. (New) The fast-dissolving pharmaceutical composition according to claim 1, wherein the mean particle size of the micronized AS-3201 is in the range of about 1.5 μ m to about 5 μ m.
- 96. (New) The fast-dissolving pharmaceutical composition according to claim 1, wherein the mean particle size of the micronized AS-3201 is in the range of about 1.5 μ m to about 3 μ m.
- 97. (New) The fast-dissolving pharmaceutical composition according to claim 1, wherein the solid dosage form is tablets, capsules, granules or powder.
- 98. (New) The fast-dissolving pharmaceutical composition according to claim 5, wherein the mean particle size of the micronized AS-3201 is above about 1.2 μm.
- 99. (New) The fast-dissolving pharmaceutical composition according to claim 5, wherein the mean particle size of the micronized AS-3201 is above about 1.5 μm.
- 100. (New) The fast-dissolving pharmaceutical composition according to claim 5, wherein the mean particle size of the micronized AS-3201 is in the range of about 1.2 μ m to about 5 μ m.
- 101. (New) The fast-dissolving pharmaceutical composition according to claim 5, wherein the mean particle size of the micronized AS-3201 is in the range of about 1.5 μ m to about 5 μ m.

- 102. (New) The fast-dissolving pharmaceutical composition according to claim 5, wherein the mean particle size of the micronized AS-3201 is in the range of about 1.5 μ m to about 3 μ m.
- 103. (New) The fast-dissolving pharmaceutical composition according to claim 5, wherein the solid dosage form is tablets, capsules, granules or powder.
- 104. (New) The fast-dissolving pharmaceutical composition according to claim 13, wherein the mean particle size of the micronized AS-3201 is above about 1.2 μ m.
- 105. (New) The fast-dissolving pharmaceutical composition according to claim 13, wherein the mean particle size of the micronized AS-3201 is above about 1.5 μ m.
- 106. (New) The fast-dissolving pharmaceutical composition according to claim 13, wherein the mean particle size of the micronized AS-3201 is in the range of about 1.2 μ m to about 5 μ m.
- 107. (New) The fast-dissolving pharmaceutical composition according to claim 13, wherein the mean particle size of the micronized AS-3201 is in the range of about 1.5 μ m to about 5 μ m.
- 108. (New) The fast-dissolving pharmaceutical composition according to claim 13, wherein the mean particle size of the micronized AS-3201 is in the range of about 1.5 μ m to about 3 μ m.
- 109. (New) The fast-dissolving pharmaceutical composition according to claim 13, wherein the solid dosage form is tablets, capsules, granules or powder.
- 110. (New) The fast-dissolving pharmaceutical composition according to claim 89, wherein the mean particle size of the micronized AS-3201 is above about 1.2 μ m.

- 111. (New) The fast-dissolving pharmaceutical composition according to claim 89, wherein the mean particle size of the micronized AS-3201 is above about 1.5 μ m.
- 112. (New) The fast-dissolving pharmaceutical composition according to claim 89, wherein the mean particle size of the micronized AS-3201 is less than about 5 μm.
- 113. (New) The fast-dissolving pharmaceutical composition according to claim 89, wherein the mean particle size of the micronized AS-3201 is in the range of about 1.2 μ m to about 5 μ m.
- 114. (New) The fast-dissolving pharmaceutical composition according to claim 89, wherein the mean particle size of the micronized AS-3201 is in the range of about 1.5 μ m to about 5 μ m.
- 115. (New) The fast-dissolving pharmaceutical composition according to claim 89, wherein the mean particle size of the micronized AS-3201 is in the range of about 1.2 μ m to about 3 μ m.
- 116. (New) The fast-dissolving pharmaceutical composition according to claim 89, wherein the mean particle size of the micronized AS-3201 is in the range of about 1.5 μ m to about 3 μ m.
- 117. (New) The fast-dissolving pharmaceutical composition according to claim 89, wherein the solid dosage form is tablets, capsules, granules or powder.